July 14, 2009 – Despite the fact that drug-eluting stent (DES) implantation reduces restenosis and the need for target vessel revascularization (TVR), these stents appear to be associated with unfavorable long-term outcomes in patients with moderate or severe renal insufficiency (RI), according to a study in this week’s issue of the International Journal of Cardiology, Volume 136, Issue 1, pag

July 13, 2009 – Premier Heart said today the CPT Editorial Panel of the American Medical Association has granted a CPT Category III code to Premier Heart's Multifunction CardioGram (MCG) system.

July 13, 2009 – Boston Scientific today announced CE mark for its LATITUDE Patient Management system, used to remotely monitor patients with implantable cardiac devices.

July 13, 2009 - On July 7 the American College of Radiology Imaging Network (ACRIN) started its first cardiovascular trial, ACRIN PA 4005 “Randomized Controlled Study of a Rapid 'Rule Out' Strategy Using CT Coronary Angiography Versus Traditional Care for Low-Risk ED Patients with Potential Acute Coronary Syndromes.”

July 13, 2009 – Daiichi Sankyo Inc. and Eli Lilly and Company said Friday the FDA approved Effient (prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with percutaneous coronary intervention (PCI).

July 13, 2009 - In a study performed at the University of Washington School of Medicine, Seattle, WA, researchers found that the use of cardiac CT for low-risk chest pain patients in the emergency department, instead of the traditional standard of care (SOC) workup, may reduce a patient's length of stay and hospital charges.

July 10, 2009 – New information added this week to the Centers for Medicare and Medicaid Services’ (CMS) Hospital Compare Web site shows patients frequently return to a hospital after discharge, a possible indicator of how well the facility did the first time around.

July 10, 2009 – Merck & Co. Inc. and Portola Pharmaceuticals Inc. this week signed an exclusive global collaboration and license agreement for the development and commercialization of betrixaban, an investigational oral factor Xa inhibitor anticoagulant currently in phase II clinical development for the prevention of stroke in patients with atrial fibrillation (SPAF).

July 10, 2009 – New British Heart Foundation (BHF) research(1) revealed today suggests for the first time that the way blood flows through our arteries may boost an antioxidant effect of statin medicines.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now